US$ 23.13
glp-1 obesity drugs pipeline Can Novo Nordisk's transform treatment? Obesity Drug Pipeline Expands with
Description
The utility of GLP-1 receptor agonists continues to expand as healthcare providers and patients seek holistic treatments for complex metabolic syndromes, strengthening their position in modern therapeutic regimens
Oral semaglutide

Now, researchers are exploring new iterations, including oral versions and multi-pathway therapies
Under this plan, Medicare recipients are expected to be covered for GLP-1s, with a $50 monthly cap on patient out-of-pocket spending

For information about the UTSW Weight Wellness Program, call 214-645-2800 or request an appointment online
